[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adult":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,47,87,120,143,170,192,211,228,249,274,318,357,387,409,430,457,483,526,553,577,599,625,654,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645077","phase-2-a-study-of-hf1k16-combined-with-bevacizumab-in-patients-with-recurrent-or-progressive-glioma-100645077",false,"NCT07678684","A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","A Multicenter, Open-Label, Adaptive Phase Ⅱ Clinical Study of HF1K16 Combined With Bevacizumab in Recurrent or Progressive Glioma","Inclusion Criteria:\n\n1. The patient and\u002For guardian must voluntarily sign and date a written informed consent form.\n2. Age ≥ 18 years and ≤ 75 years at the time of informed consent signing, male or female.\n3. Confirmed diagnosis of glioma by histopathology and molecular pathology, with recurrent or progressive disease following prior therapy, and no available standard treatment or intolerance to standard treatment.\n4. Expected survival time of at least 3 months.\n5. Karnofsky Performance Status (KPS) score ≥ 60.\n6. Adequate organ and bone marrow function as defined by the following criteria:\n\n   * Bone marrow reserve: absolute neutrophil count ≥ 1.5×10⁹\u002FL, platelet count ≥ 90×10⁹\u002FL, and hemoglobin ≥ 9.0 g\u002FdL (without transfusion or hematopoietic growth factor support within 14 days);\n   * Coagulation function: activated partial thromboplastin time (APTT) ≤ 1.5×ULN, and international normalized ratio (INR) ≤ 1.5×ULN;\n   * Hepatic function: total bilirubin (TBIL) ≤ 1.5×ULN, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; in the presence of liver metastases, ALT and AST ≤ 5×ULN and TBIL ≤ 3×ULN;\n   * Renal function: creatinine clearance ≥ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n   * Left ventricular ejection fraction (LVEF) ≥ 50%;\n   * QTcF interval on electrocardiogram \\\u003C 450 ms (males) or \\\u003C 470 ms (females).\n7. Subjects of reproductive potential (including male subjects) must agree to avoid pregnancy and use effective contraceptive measures with their partners during the study period and for 6 months after the last dose. A negative serum pregnancy test must be confirmed between screening and prior to the first dose.\n\nExclusion Criteria:\n\n1. Any active autoimmune disease, or a history of autoimmune disease requiring systemic steroid therapy, with a daily prednisone dose \\> 10 mg or equivalent corticosteroid within 2 weeks prior to study treatment.\n2. Uncontrolled seizures, hypertension, or psychiatric disorder at screening.\n3. Severe infection occurring within 4 weeks prior to the first dose, including but not limited to complicated infection requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective therapy within 2 weeks prior to the first dose, except for antiviral therapy for hepatitis B or hepatitis C.\n4. Third-space effusion that cannot be effectively controlled by drainage or other measures.\n5. Participation in another clinical trial of an investigational drug within 4 weeks prior to enrollment.\n6. Receipt of any anti-tumor therapy including chemotherapy, targeted therapy, biologic therapy, immunotherapy, radical radiotherapy, or major surgery within 2 weeks prior to enrollment or within 3 half-lives (whichever is shorter).\n7. Any other active malignancy within 5 years prior to enrollment. Subjects with other malignancies cured by local therapy (e.g., basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix) are excepted.\n8. Patients with hyperthyroidism are excluded. Subjects with hypothyroidism on a stable dose of thyroid hormone replacement therapy with stable thyroid function (TSH ≤ 10 μIU\u002FmL and no clinical manifestations of hypothyroidism) may be enrolled.\n9. Failure to recover from all adverse events due to prior therapy to Grade ≤ 1 (per CTCAE v5.0) or to baseline levels, except for toxicities deemed by the investigator to pose no safety risk (such as alopecia, Grade 2 peripheral neuropathy, hypothyroidism stabilized with hormone replacement therapy, etc.).\n10. Any active cardiac disease within 6 months prior to the first dose, including New York Heart Association (NYHA) Class II-IV cardiac dysfunction, congestive heart failure, myocardial infarction, unstable angina, and\u002For stroke or other cardiovascular or cerebrovascular events of Grade 3 or higher, or left ventricular ejection fraction (LVEF) \\\u003C 50%.\n11. HIV infection, active HBV infection (HBV DNA above the upper limit of normal), or active HCV infection (HCV RNA above the upper limit of normal).\n12. Any other serious systemic disease or any other condition that, in the opinion of the investigator, would render the subject ineligible for participation in this clinical study.","ALL","18 Years","75 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.",[28,29],"Glioma","Adult",[31,32,33],"Drug Combinations","Drug Safety","Drug Tolerance","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":22},"2026-06-30",{"date":42,"type":22},"2028-12-31",{"name":44,"class":45},"HighField Biopharmaceuticals Corporation","INDUSTRY",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":46},"100644242","hydroponic-vs-conventional-spinach-smoothies-effects-on-salivary-nitrate-bioavailability-and-blood-pressure-100644242","NCT07665944","Hydroponic vs Conventional Spinach Smoothies: Effects on Salivary Nitrate Bioavailability and Blood Pressure","Acute Effects of Hydroponically vs. Conventionally Grown Spinach Smoothies on Salivary Nitrate Bioavailability and Blood Pressure: A Randomized Controlled Crossover Trial","SPIN-BP-NO","Inclusion Criteria:\n\n* Adults aged 18-60 years\n* Generally healthy individuals (no diagnosed chronic disease)\n* Non-smokers and non-vapers\n* Not currently taking medications known to affect cardiovascular function or nitrate metabolism\n* Able and willing to provide informed consent\n* Willing to comply with study procedures and attend both study visits\n\nExclusion Criteria:\n\n* Presence of chronic disease (e.g., cardiovascular, metabolic, renal, or respiratory conditions)\n* Use of pacemakers or implanted medical devices\n* Pregnant or lactating individuals\n* Known allergy or intolerance to spinach\n* History of gastrointestinal disorders or pathology affecting digestion or absorption\n* Use of nitrate or nitrite supplements\n* Use of antibiotics within the past 3 weeks\n* Use of antibacterial mouthwash or oral products within the past 2 weeks\n* Current participation in another clinical trial or recent participation that may interfere with outcomes",true,"60 Years",{"count":58,"type":22},12,[60],"NA","The goal of this clinical trial is to determine whether hydroponic spinach (HS) versus conventional spinach (CS) smoothies produce differential post-consumption effects on salivary nitrate availability and blood pressure in adults.\n\nThe main questions it aims to answer are:\n\nDo hydroponic spinach (HS) and conventional spinach (CS) smoothies produce differential post-consumption salivary nitrate availability responses in adults when consumed in equal volumes? Do hydroponic spinach (HS) and conventional spinach (CS) smoothies produce differential post-consumption blood pressure responses in adults when consumed in equal volumes?\n\nParticipants will:\n\nConsume hydroponic spinach (HS) and conventional spinach (CS) smoothies on two separate study days.\n\nAttend two laboratory visits at the university, scheduled within a 1-2 week period.\n\nUndergo check-ups and study measurements during each visit (e.g., blood pressure and saliva sampling).",[29],[64,65,66,67,68,69,70,71,72,73,74,75,76],"spinach","Hydroponic agriculture","Conventional agriculture","Dietary nitrate","Nitrite","Nitric oxide","Blood pressure","Crossover study","Randomized controlled trial","Smoothie intervention","Postprandial response","Saliva biomarkers","Nitrate bioavailability","RECRUITING","2026-06-18",{"date":35,"type":38},{"date":81,"type":38},"2026-05-22",{"date":83,"type":22},"2026-07-31",{"name":85,"class":86},"University of Plymouth","OTHER",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":105,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":4,"leadSponsor":117,"locationsCount":46},"100057075","study-of-new-magnetic-resonance-imaging-methods-of-the-brain-100057075","NCT00004577","Study of New Magnetic Resonance Imaging Methods of the Brain","Characterization of Brain Morphology and Activity Using Functional and Anatomical MRI Contrast","* INCLUSION CRITERIA:\n* 18 years of age and older\n* in good general health\n* able to understand the procedures and requirements and give informed consent\n\nEXCLUSION CRITERIA:\n\nAll Subjects will undergo a neurological physical and answer the Healthy volunteer form, and the most-recent version of the NMR safety screening form\n\nA subject will be excluded if he\u002Fshe:\n\n1. has any metal implant or objects of unknown identity or composition, or if it s known to be non-compatible with MRI, such as pacemakers, medication pumps, aneurysm clips, metallic prosthesis (such as heart valves or cochlear implants), certain orthopedic implants (pins and rods), shrapnel, or small metal fragments in the eye;\n2. has claustrophobia;\n3. cannot lie comfortably for up to 120 minutes;\n4. underwent brain surgery or suffered a traumatic head trauma;\n5. has migraines that require medication;\n6. has ever been hospitalized for a psychiatric disorder;\n7. has medical health problems such as pulmonary or airway disease, heart failure, coronary artery disease, and uncontrolled hypertension which would require physiological monitoring during the scan;\n8. has a history of any medical condition that could result in an emergency medical situation while undergoing the MRI scan;\n9. has hearing problems which would make it difficult to tolerate scanner noise;\n10. is pregnant;\n11. has body\u002Fmake-up tattoos (e.g. lips, eyebrows, eyeliner). Each tattoo will be considered on a case-to-case basis, taking into account of the age and location of the tattoo;\n12. has a sleep apnea diagnosis;\n13. has a neurological disorder, such as Stroke, Parkinson s, and Epilepsy;\n14. a member of the NINDS Laboratory of Functional and Molecular Imaging.\n\nThe contraindications to MRI at the various field strengths are almost identical, except the 7 T also excludes subjects with gold dental crowns.","120 Years",{"count":96,"type":22},1100,"OBSERVATIONAL","The purpose of this investigation is to develop improved magnetic resonance imaging (MRI) techniques and hardware for studying brain function. MRI is a diagnostic tool that provides information about brain chemistry and physiology. This study will evaluate new MRI methods for monitoring blood flow to regions of the brain in response to simple tasks. The MRI machine used in this study is more powerful than those in most hospitals, permitting a higher visual resolution.\n\nNormal healthy volunteers over 18 years old may be eligible for this study. Candidates will be screened with a medical history and questionnaire, and a neurological examination. Study participants will have a yearly MRI scan. For this procedure, the subject lies on a stretcher that is moved into a donut-shaped machine with a strong magnetic field. A lightweight circular or rectangular coil-a device that improves the quality of the images-may be placed on the head. The scan time varies from 20 minutes to 3 hours; most scans last between 45 and 90 minutes. During the scan, the subject may perform simple tasks, such as listening to tapes, tapping a finger, moving a hand, watching a screen, or smelling a fragrance. More complex tasks may require thinking about tones or pictures and responding to them by pressing buttons.\n\nInformation from this study will be used to develop better imaging methods that will, in turn, permit a greater understanding of normal and abnormal brain behaviors.",[100,101,102,103,104,29],"Healthy Volunteer","Magnetic Resonance Imaging","Healthy","fMRI","Brain Mapping",[106,107,108,109,110,111],"Brain Morphology","Cerebral Blood Volume","Functional Imaging","Development","MEG","Natural History","2026-06-16",{"date":114,"type":38},"2026-06-17",{"date":116,"type":38},"2000-07-01",{"name":118,"class":119},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":46},"100638079","evaluation-of-an-instructional-video-about-medication-management-during-admission-and-medication-adherence-for-kidney-transplantation-and-in-the-outpatient-clinic-in-a-dutch-university-hospital-100638079","NCT07592624","Evaluation of an Instructional Video About Medication Management During Admission and Medication Adherence for Kidney Transplantation and in the Outpatient Clinic in a Dutch University Hospital.","MediT","Inclusion Criteria:\n\n* The patient is able to take the medication independently or with the help of someone else (professionals not included).\n* After admission, the patient is discharged to their own home or home of friend\u002Frelative.\n* The patient had a follow up at the outpatient clinic in the Erasmus Medical Center for at least one year after transplantation.\n* The patient is able to read the medication list or an illiteracy-friendly medication list.\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients who got discharged with a medication dispenser\n* Refusal to participate in the study.\n* Cognitive impairments that hinder participation.\n* Patients and\u002For family who can not understand (language barrier) the instructional video.",{"count":128,"type":22},308,[60],"The goal of this RCT is to evaluate the effect of the instructional video on improving patient compliance and reducing medication errors. The study will include adult kidney transplant recipients (18 years or older) at Erasmus MC who have undergone a kidney transplantation starting January 2026.\n\nThe main questions it aims to answer:\n\nThe primary aim of this study is to assess whether our developed video instruction, compared with the traditional verbal instruction, both of which are given shortly before training during admission, reduces the number of medication errors in kidney transplant patients.\n\nThe study will also examine the correlation between patient characteristics (such as age, comorbidities, and language proficiency) and medication errors. Additionally, patient-reported medication errors will be measured through a questionnaire completed during follow-up visits at the outpatient clinic, which is part of standard care.\n\nThe instructional video will be evaluated by a short questionnaire.",[132,29,133,134],"Kidney Transplant","Medication Adherence","Instruction Videos","2026-05-11",{"date":137,"type":38},"2026-05-18",{"date":37,"type":22},{"date":140,"type":22},"2027-12-31",{"name":142,"class":86},"Erasmus Medical Center",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":46},"100638844","biomarkers-in-bone-marrow-supernatant-for-predicting-aml-chemosensitivity-100638844","NCT07587944","Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity","Bone Marrow Microenvironment Signatures for Predicting AML Prognosis and Resistance","Inclusion Criteria:\n\n1. Clinical diagnosis aligns with the \"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)\";\n2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;\n3. Patients participate in the study accompanied by family members and sign informed consent documents.\n\nExclusion Criteria:\n\n1. Patients with concurrent malignancies requiring treatment;\n2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV\u002F AIDS;\n3. Major surgery performed within the last 21 days;\n4. Performance Status (PS) score \\>3;\n5. Severe liver or kidney dysfunction or serious infection;\n6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.",{"count":151,"type":22},405,"Chemoresistance in acute myeloid leukemia (AML) is closely associated with the bone marrow microenvironment. Elevated levels of IL-6, leptin, fumarate, and other factors within the bone marrow microenvironment have been shown to enhance oxidative phosphorylation or antioxidant capacity in AML cells, thereby inducing chemoresistance. To explore their potential as prognostic biomarkers or therapeutic targets, this study plans to enroll 405 newly diagnosed AML patients meeting the criteria of the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2023 Edition), along with 81 sex- and age-matched healthy controls. By analyzing the levels of IL-6, leptin, fumarate, and other factors in patient bone marrow supernatant, we will evaluate their associations with treatment response (primary endpoints: overall survival \\[OS\\] and overall response rate \\[ORR\\] after one cycle of chemotherapy) and prognosis. Furthermore, patient-derived xenograft (PDX) mouse models established from primary AML cells will be used to validate their roles in chemoresistance, aiming to provide a basis for therapies targeting the bone marrow microenvironment.",[154,29],"AML",[154,156,157,158,159,160],"Chemosensitivity","Biomarker","Fumarate","Leptin","IL-6","2026-05-08",{"date":163,"type":38},"2026-05-14",{"date":165,"type":38},"2025-12-01",{"date":167,"type":22},"2030-01-01",{"name":169,"class":86},"Fujian Medical University Union Hospital",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":46},"100579053","phase-1-ib-t101-injection-for-treatment-of-patients-with-advanced-clear-cell-renal-cell-carcinoma-100579053","NCT06819293","IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma","A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;\n2. Age ≥18 years old;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n4. Expected survival time of ≥ 3 months;\n\nExclusion Criteria:\n\n1. CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia\u002Fhemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS.\n2. Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects\n3. Have experienced myocardial infarction or unstable angina within the 6 months prior to screening\n4. Pleural effusion requiring drainage for symptom management within 28 days prior to screening",{"count":58,"type":22},[179],"PHASE1","This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma",[182,29],"Advanced Clear Renal Cell Carcinoma","2026-04-13",{"date":185,"type":38},"2026-04-14",{"date":187,"type":38},"2024-12-06",{"date":189,"type":22},"2027-12-07",{"name":191,"class":45},"Grit Biotechnology",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":46},"100579052","autologous-tumor-infiltrating-lymphocyte-gt307-for-treatment-of-patients-with-advanced-colorectal-cancer-100579052","NCT06819280","Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer","A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer","Inclusion Criteria:\n\n1. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;\n2. Age 18 to 70 years old;\n3. Advanced Colorectal Cancer that progresses after first-line chemotherapy；\n4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n5. Expected survival time of ≥ 12 weeks;\n6. Good function of vital organs;\n7. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;\n8. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.\n\nExclusion Criteria:\n\n1. Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;\n2. Known mental illness, alcoholism, drug use or substance abuse;\n3. Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;\n4. Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;\n5. The investigators determine that other conditions that make the patient not suitable for enrollment","70 Years",{"count":201,"type":22},18,[60],"This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with Advanced Colorectal Cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).",[29],{"date":185,"type":38},{"date":207,"type":38},"2024-06-28",{"date":209,"type":22},"2027-05-27",{"name":191,"class":45},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":46},"100550898","autologous-tumor-infiltrating-lymphocyte-gt307-for-treatment-of-patients-with-solid-tumours-100550898","NCT06453057","Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours","A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours","Inclusion Criteria:\n\n* 1\\. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;\n* 2\\. Age 18 to 70 years old;\n* 3\\. Ovarian cancer that progresses after recurrence or first-line chemotherapy；\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n* 5\\. Expected survival time of ≥ 12 weeks;\n* 6\\. Good function of vital organs;\n* 7\\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;\n* 8\\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.\n\nExclusion Criteria:\n\n* 1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;\n* 2.Known mental illness, alcoholism, drug use or substance abuse;\n* 3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;\n* 4.Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;\n* 5.The investigators determine that other conditions that make the patient not suitable for enrollment.",{"count":201,"type":22},[60],"This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).",[29],{"date":185,"type":38},{"date":224,"type":38},"2024-07-04",{"date":226,"type":22},"2027-06-06",{"name":191,"class":45},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":235,"minAge":18,"maxAge":199,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":248},"100534665","phase-2-autologous-tumor-infiltrating-lymphocytes-gt101-injection-in-patients-with-recurrent-or-metastatic-cervical-cancer-100534665","NCT06241781","Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","Inclusion Criteria:\n\n* 1\\. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board\u002FIndependent Ethics Committee (IRB\u002FIEC) ,must have the ability to understand the requirements of the study);\n* 2\\. The patient must be 18 to 70 years of age at the time of consent;\n* 3\\. Must have a confirmed diagnosis of malignancy of their receptive histologies or cytology: unresectable recurrent or metastatic cervical carcinomas and previously received≥ 1 prior systemic therapy;\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n* 5\\. Expected survival time of ≥ 12 weeks;\n* 6\\. Adequate normal organ and marrow function;\n* 7\\. Before tumor resection, the confirmatory imaging of disease progress since last treatment should be documented.\n* 8.Patients must have measurable disease measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (in addition to the resected lesion).\n\nExclusion Criteria:\n\n* 1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring painkiller must already have had a stable pain management options at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;\n* 2.Patients who have psychiatric disorders, alcohol, drug or substance abuse;\n* 3.Women who are pregnant or breastfeeding, or planning to become pregnant within 1 year after cell infusion;\n* 4.Participate in other clinical trials within 4 weeks prior to screening, or planning to participate in this study and other clinical trials at the same time;\n* 5.Any other conditions that would make the patient unsuitable candidate for the study at the discretion of the investigator.","FEMALE",{"count":237,"type":22},83,[25],"This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.",[29],{"date":242,"type":38},"2026-04-15",{"date":244,"type":38},"2024-04-02",{"date":246,"type":22},"2027-01-31",{"name":191,"class":45},24,{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":55,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":46},"100631300","lasaion-is-an-evidence-informed-multimodal-self-regulation-program-designed-to-reduce-emotional-distress-and-strengthen-stress-regulation-skills-by-combining-transcutaneous-auricular-vagus-nerve-stimulation-tavns-with-breathing-supported-by-heart-rate-variability-biofeedback-hrv-b-emwave-100631300","NCT07498881","LasaiON is an Evidence-informed, Multimodal Self-regulation Program Designed to Reduce Emotional Distress and Strengthen Stress-regulation Skills by Combining Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) With Breathing Supported by Heart-rate Variability Biofeedback (HRV-B; emWave).","LasaiOn: An Intervention Program to Reduce Emotional Distress","LasaiON","Inclusion Criteria:\n\n* Ability to provide written informed consent\n* Physically healthy, with no relevant uncontrolled medical condition\n* Availability to complete the 5-day study protocol (1 session\u002Fday), including baseline and post-intervention assessments\n* Intact external ear and suitability for electrode placement on the tragus and acquisition of study recordings (EEG, EDA, HRV)\n\nExclusion Criteria:\n\n* History of cardiovascular disease, diabetes, or hypertension\n* Severe bradycardia\n* Active implanted electronic device (e.g., pacemaker, cochlear implant, neurostimulator)\n* History of vagus nerve transection surgery (cervical vagotomy)\n* Pregnancy\n* Current or past clinically significant psychiatric disorder\n* Current or past clinically significant neurological disorder\n* Use of CNS-active medication\n* Substance misuse, including nicotine or alcohol\n* Dermatitis, infection, or lesions of the ear that could interfere with electrode application\n* Ongoing treatment with medications that modulate autonomic nervous system activity or may alter psychophysiological measures (e.g., HRV, EDA, EEG)",{"count":258,"type":22},200,[60],"The goal of this clinical trial is to evaluate whether the LasaiON program, which combines transcutaneous auricular vagus nerve stimulation (taVNS) with breathing supported by heart rate variability biofeedback (HRV-B; emWave), reduces emotional distress and improves stress-regulation processes in adults. The study will also assess the safety, tolerability, and feasibility of the intervention.\n\nThe main questions it aims to answer are:\n\n1. Does the LasaiON program reduce emotional distress in adults?\n2. What physiological, psychological, and verbal-cognitive changes are observed following the intervention?\n3. What discomforts, adverse effects, or tolerability issues do participants experience during the program?\n\nResearchers will use a prospective 2 × 2 factorial randomized controlled design to examine the effects of stimulation condition (active taVNS vs. sham taVNS) and training condition (active HRV-biofeedback vs. control training), as well as their potential interaction. Participants will be randomly allocated in equal proportions (1:1:1:1) to one of four groups: sham taVNS + control training, sham taVNS + HRV-biofeedback, active taVNS + control training, or active taVNS + HRV-biofeedback.\n\nParticipants will:\n\n* undergo baseline assessments on Day 1 before the intervention;\n* complete 5 consecutive daily 60-minute sessions according to group allocation;\n* undergo post-intervention assessments on Day 5 after the final session;\n* complete psychometric, physiological, and verbal-cognitive assessments, including STAI, HAM-D, WHO-5, EEG, skin conductance, startle response, heart rate variability measures derived using Kubios HRV Premium, and daily five-word reports with valence ratings analyzed using IRaMuTeQ;\n* have adherence and tolerability recorded at each session using a checklist.",[29],[263,264],"slow, paced breathing","transauricualr vagus nerve stimulation","2026-03-23",{"date":267,"type":38},"2026-03-27",{"date":269,"type":22},"2026-03-30",{"date":271,"type":22},"2028-03-30",{"name":273,"class":86},"University of the Basque Country (UPV\u002FEHU)",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":281,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":295,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":46},"100582737","peanuts-for-cardiometabolic-brain-and-intestinal-health-100582737","NCT06867198","Peanuts for Cardiometabolic, Brain, and Intestinal Health","Impact of Peanuts on Cardiometabolic, Cognitive, and Intestinal Health in Prediabetes Among Racially Diverse Populations","Inclusion Criteria:\n\n* men and women\n* 20-59 years of age\n* BMI: 24.5 - 35.5 kg\u002Fm\\^2\n* Prediabetes (fasting blood glucose levels 100-125 mg\u002FdL and\u002For HbA1c between 5.7-6.4%)\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to peanuts and peanut products\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological diseases or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n\nMRI Exclusion Criteria:\n\n* Certain neurological disorders (e.g., uncontrolled seizure disorders)\n* Braces on their teeth, a cardiac pacemaker; hearing aid; other metal in the body or eyes (which may include certain metallic-embedded tattoos), including but not limited to pins, screws, shrapnel, plates, dentures or other metal objects","20 Years","59 Years",{"count":284,"type":22},72,[60],"The overall objective of this 14-month randomized crossover study is to seek evidence demonstrating that daily consumption of peanuts and peanut products improve cardiometabolic, cognitive, and intestinal health in a racially diverse prediabetes population.",[288,289,290,291,292,293,294,29],"Prediabetes","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Cognition","Microvascular Function","Gut Microbiota","Endothelial Function (Reactive Hyperemia)","Arterial Stiffness, Blood Pressure",[296,297,298,299,300,301,302,303,304,305,306,307,308,309,310],"prediabetes","peanuts","functional foods","nuts","metabolic health","insulin resistance","type II diabetes","microvascular function","dietary intervention","cognitive function","vascular function","neuroimaging","endothelial function","cardiovascular health","gut microbiota",{"date":267,"type":38},{"date":313,"type":38},"2025-03-06",{"date":315,"type":22},"2027-09",{"name":317,"class":86},"Georgia State University",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":344,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":46},"100572617","wild-blueberries-for-gut-brain-and-heart-health-in-adults-with-high-blood-pressure-100572617","NCT06735599","Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure","Effects of Wild Blueberry Consumption on Gut, Brain, and Cardiovascular Health in Non-Hispanic Black and White Adults With High Blood Pressure","Inclusion Criteria:\n\n* Individuals 45-65 years of age\n* Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and\u002For diastolic blood pressure = 80-89 mmHg) for at least 6 months\n* BMI 25-35 kg\u002Fm2 via anthropometric measurements.\n* Ability to give consent\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of one hypertensive drug for less than three months\n* Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury\n* Smoking\n* Alcohol consumption (\\>2 drinks\u002Fday)\n* Consuming antioxidant, probiotic, and prebiotic supplements\n* Pregnant or lactating\n* Participating in a weight loss program","45 Years","65 Years",{"count":328,"type":22},40,[60],"The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.",[332,333,334,335,29,290,293,336,337,338,339,340,341,342,343,291],"Hypertension (Without Type 2 Diabetes Mellitus)","High Blood Pressure","Male","Female","Oxidative Stress","Diet","Overweight","Body Composition Measurement","Gut Microbiome","Arterial Stiffness","Caucasian Whites","Inflammation",[345,346,338,333,347,348,349,298,310,350,303],"Blueberries","Hypertension","Endothelial Function","Cognitive Function","Dietary intervention","arterial stiffness",{"date":267,"type":38},{"date":353,"type":38},"2024-09-17",{"date":355,"type":22},"2027-01-01",{"name":317,"class":86},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":235,"minAge":281,"maxAge":326,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":46},"100572621","wild-blueberries-for-gut-brain-and-cardiometabolic-health-in-prediabetes-100572621","NCT06735651","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes","Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Female Adults With Prediabetes.","Inclusion Criteria:\n\n* Women aged 20-65 years old\n* Prediabetes (fasting blood glucose 100-125 mg\u002FdL and\u002For HbA1c percentage between 5.7-6.4)\n* Body Mass Index between 25-30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Allergies to berries\n* Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs\n* Active cancer, gastrointestinal, renal, thyroid, stage 1 \\& 2 hypertension and other cardiovascular diseases, neurological diseases, or severe head injury\n* Smoking\n* Consumes greater than 2 alcoholic beverages per day\n* Consumes antioxidant, probiotic, and prebiotic supplements\n* Pregnant or Lactating\n* Actively participating in a weight loss program\n* Currently taking berry supplements or recently participated in another study taking berry supplements",{"count":21,"type":22},[60],"The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.",[289,335,29,293,341,290,336,292,338,343,291,368],"Body Composition",[345,288,370,371,349,372,373,374,375,376,377,378,291,379],"Insulin Resistance","Functional foods","Endothelial function","Vascular function","Cardiovascular health","Metabolic health","Gut microbiota","Cognitive function","Type II diabetes","Wild Blueberries",{"date":381,"type":38},"2026-03-25",{"date":383,"type":38},"2024-09-20",{"date":385,"type":22},"2026-06-01",{"name":317,"class":86},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":406,"leadSponsor":407,"locationsCount":46},"100631043","comparison-of-the-effects-of-free-weight-and-machine-based-exercises-on-muscular-parameters-100631043","NCT07495540","Comparison of the Effects of Free Weight and Machine-Based Exercises on Muscular Parameters","Comparison of Free Weight and Machine-Based Exercise Effects on Muscular Parameters","Inclusion Criteria:\n\n* Being an individual between the ages of 18-30 years\n* Being physically inactive according to the International Physical Activity Questionnaire short form (\\\u003C600 MET-min\u002Fweek)\n* Residing in Istanbul\n* Voluntary participation in the study.\n\nExclusion Criteria:\n\n* Having a neurological or cardiopulmonary system problem that prevents exercise.\n* Having mental dysfunction.\n* Having an acute musculoskeletal injury which limits exercise participant\n* Being pregnant.\n* Having answered \"YES\" to any question on the Exercise Readiness Questionnaire.","30 Years",{"count":396,"type":22},26,[60],"The aim of our study is to compare and investigate the effects of resistance exercises performed with free weights and those performed using machine systems on muscular parameters and neuromuscular control.",[400,401,402,29],"Resistance Exercise","Neuromuscular Adaptations","Muscle","2026-03-21",{"date":267,"type":38},{"date":265,"type":22},{"date":385,"type":22},{"name":408,"class":86},"Biruni University",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":326,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":46},"100629895","efficacy-of-indonesian-asthmatic-gymnastic-as-combine-pulmonary-rehabilitation-based-on-asthma-classification-100629895","NCT07480616","Efficacy of Indonesian Asthmatic Gymnastic as Combine Pulmonary Rehabilitation Based on Asthma Classification","EFFICACY OF INDONESIAN ASTHMATIC GYMNASTIC AS COMBINE PULMONARY REHABILITATION IN ASTHMATIC PATIENT BASED ON ASTHMA CLASSIFICATION","Inclusion Criteria:\n\n* Diagnosed with stable asthma\n* Age 18-65 years old\n* Competent and willing to be included in the trial\n\nExclusion Criteria:\n\n* Asthma exacerbation\n* Had other lung disease\n* Had neuromuscular disease affecting respiratory system",{"count":5,"type":22},[60],"This study aims to evaluate the efficacy of Indonesian Asthma Gymnastic for stable asthmatic patients in all asthma classification. The outcome measurements includes 6 minutes walk test, Asthma Control Test, peak flow rate value, and lung function. All participants have been in routine standard treatment of asthma (medication, education of healthy life style and smoking cessation).",[420,29],"Asthma (Diagnosis)","2026-03-13",{"date":423,"type":38},"2026-03-18",{"date":425,"type":38},"2025-10-06",{"date":427,"type":22},"2026-09",{"name":429,"class":86},"RSUP Persahabatan",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":438,"conditions":439,"keywords":446,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":46},"100441118","long-term-follow-up-of-subjects-treated-with-car-t-cells-100441118","NCT05024175","Long-term Follow-up of Subjects Treated With CAR T Cells","Inclusion Criteria:\n\nSubjects will be asked to participate leading up to the last DF\u002FHCC corresponding main study visit.\n\nSubjects meeting the following criteria are eligible for study participation:\n\n* Provision of voluntary written informed consent by subject\n* CAR T cells were administered in DF\u002FHCC IRB corresponding main study\n\nExclusion Criteria:\n\nSubjects meeting the following criterion are to be excluded from study participation:\n\n\\- Subject unable to comply with study requirements",{"count":437,"type":22},45,"This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF\u002FHCC# 22-175) and NCT06026319 (DF\u002FHCC# 23-474).",[440,441,442,29,443,444,445],"Long Term Adverse Effects","CAR-T","Duty to Follow Up","Progression-Free Survival","Disease-Free Survival","Overall Survival",[447,448],"Long-Term Follow-up to CAR-T Cells","Follow-up Studies",{"date":450,"type":38},"2026-03-16",{"date":452,"type":38},"2023-08-07",{"date":454,"type":22},"2039-08-01",{"name":456,"class":86},"Marcela V. Maus, M.D.,Ph.D.",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":46},"100620206","effect-of-transcutaneous-electrical-stimulation-on-peripheral-blood-flow-100620206","NCT07354607","Effect of Transcutaneous Electrical Stimulation on Peripheral Blood Flow","Effect of Transcutaneous Electrical Stimulation on Peripheral Blood Flow - a Pilot Study","VASC-STIM","Inclusion Criteria:\n\n* Subject aged 18 years or older\n* Having freely given written consent, after being informed of the purpose of the study, its conduct and its risks.\n* Affiliated with a social security scheme\n\nExclusion Criteria:\n\n* Persons with pacemakers or any other implantable electrical devices,\n* Pregnant women\n* Suffering from dermatological conditions or muscle\u002Fskin lesions on the arms and forearms.\n* Participant unable to give free and informed consent.\n* Participant unable to comply with the specific procedures of the study.\n* Participant deprived of liberty or benefiting from legal protection measures.",{"count":466,"type":22},36,[60],"The goal of this clinical trial is to learn if transcutaneous electrical nerve stimulation can affect blood flow in healthy volunteers. The main question it aims to answer is:\n\nDetermine the stimulation parameters (frequency in the range 5- 100Hz and proximal or distal placement) inducing the most significant hyperaemic response in volunteers.\n\nParticipants will attend to one visit ( 1h30) , 6 protocol of stimulation will be tested on his arm . If his agree, an optionnal measure will be made during another visit. During this optionnal visit, two modalities of intensity adjustment will be tested in regard of the result of the first part of the study.",[470,29],"Volunteer",[472,473],"transcutaneous electrical nerve stimulation","blood flow","2026-03-09",{"date":476,"type":38},"2026-03-10",{"date":478,"type":38},"2026-02-04",{"date":480,"type":22},"2026-08-01",{"name":482,"class":86},"Centre Hospitalier Metropole Savoie",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":492,"briefSummary":493,"conditions":494,"keywords":504,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":524,"locationsCount":4},"100628100","probiotic-research-open-label-functional-intervention-and-longitudinal-evaluation-in-healthy-adults-100628100","NCT07457242","Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults","PROFILE","Inclusion Criteria:\n\n* Aged 18 years or older at the time of providing informed consent.\n* In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.\n* No history of significant psychiatric or neurological illness\n* Ability to complete study specific tasks, including:\n* Daily oral intake of a probiotic capsule\n* Self-collection of stool samples\n* Completion of online questionnaires and simple cognitive tasks\n* Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.\n* Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.\n\nExclusion Criteria:\n\n* Participants will be excluded from the study if any of the following criteria apply:\n* Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:\n* β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals\n* Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:\n* Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.\n* A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.\n* Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.\n* Major gastrointestinal disease or surgery:\n* Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.\n* Current pregnancy or development of pregnancy, breastfeeding\n* Known allergy to probiotic or compounding ingredients:\n* Vitamin D3\n* Isomaltooligosaccharide\n* Yeast extract",{"count":491,"type":22},180,[60],"This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.\n\nDuring the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.\n\nThis study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.",[290,495,496,497,498,499,500,501,502,29,503],"Multiomics","Microbiome Analysis","Metabolome","Proteome","Metagenome","Probiotics Supplement","Gut-brain Axis","Pilot Study","Sleep",[505,506,507,508,509,510,511,512,513,514,515,516,517,305,518],"Probiotics","Dietary Supplements","Microbiome","Multi-omics","Metabolomics","Proteomics","Mitochondrial Function","Cellular Metabolism","Short-Chain Fatty Acids","Bioinformatics","Healthy volunteers","Pilot study","feasibility study","mental health","2026-03-03",{"date":474,"type":38},{"date":37,"type":22},{"date":523,"type":22},"2027-07-01",{"name":525,"class":45},"OneCarbon",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":535,"studyType":97,"phases":4,"briefSummary":536,"conditions":537,"keywords":540,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":4},"100626802","enterocyte-injury-and-acute-gastrointestinal-dysfunction-in-critical-illness-100626802","NCT07440368","Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness","Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness: A Prospective Observational Study of Blood and Urinary Intestinal Fatty Acid-Binding Protein(Implications for Sepsis Heterogeneity）","Inclusion Criteria:\n\n* 1、 Age ≥18 years.\n* 2 、Admission to the ICU with an expected ICU stay ≥48 hours.\n* 3 、Availability of paired plasma and urine samples within 24 hours of ICU admission.\n* 4 、Feasible daily gastrointestinal function assessment to complete AGI grading (ESICM definition).\n\nExclusion Criteria:\n\n* 1、 Pre-existing inflammatory bowel disease.\n* 2 、Short bowel syndrome.\n* 3、 Chronic intestinal failure requiring long-term parenteral nutrition.\n* 4、 Pregnancy.\n* 5 、Refusal or withdrawal of informed consent.",{"count":534,"type":22},500,"28 Days","Acute gastrointestinal injury (AGI) is a common but not fully understood organ dysfunction in critically ill patients. Current AGI grading systems rely primarily on clinical presentation and feeding tolerance, which are inherently subjective and may not accurately reflect the underlying biological severity of intestinal damage.\n\nIntestinal fatty acid-binding protein (I-FABP) is a protein expressed almost exclusively in the cytoplasm of mature small intestinal epithelial cells. In cases of ischemia, inflammation, or mechanical injury, I-FABP is rapidly released into the bloodstream and subsequently excreted in the urine. These characteristics make I-FABP a highly specific biomarker for intestinal epithelial cell injury and intestinal ischemia.\n\nA prospective study combining paired blood and urine I-FABP measurements, standardized AGI assessment, and careful consideration of surgical status was conducted to elucidate the role of intestinal epithelial cell injury in acute gastrointestinal dysfunction.",[538,539,29],"Patients Admitted to the ICU","Expected Hospital Stay ≥48 Hours",[541,542,543],"Intestinal Fatty Acid-Binding Protein","Acute Gastrointestinal Dysfunction","Critical Illness","2026-02-23",{"date":546,"type":38},"2026-02-27",{"date":548,"type":22},"2026-03-01",{"date":550,"type":22},"2026-12-01",{"name":552,"class":86},"The First Hospital of Jilin University",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":535,"studyType":97,"phases":4,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":4},"100624786","association-between-dynamic-prealbumin-trajectories-and-prognosis-in-critically-ill-patients-100624786","NCT07414160","Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients","Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients: A Prospective Observational Study","PAB-TRACK","Inclusion Criteria:\n\n1. age \\> 18 years,\n2. SOFA score ≥ 2\n3. at least three prealbumin data points within the previous 14 days.\n\nExclusion Criteria:\n\n1. patients with liver failure\n2. patients with kidney failure,\n3. hereditary amyloidosis and Alzheimer's disease\n4. long-term use of hormones or NSAIDs. -",{"count":534,"type":22},"Nutritional support therapy is a crucial part of ICU patient care, as both malnutrition and overnutrition can lead to adverse clinical outcomes. Meticulous monitoring of nutritional support is essential. Unfortunately, to date, there are no biomarkers available to assess the appropriateness of nutritional support in the ICU setting. However, mounting evidence suggests that phenotypic analysis of patients using nutritional biomarkers or risk screening scores for adaptation may enhance our ability to characterize patients in terms of prognosis and likelihood of treatment response.\n\nThis study aims to identify the trajectory patterns of prealbumin changes based on dynamic monitoring data of prealbumin during hospitalization of critically ill patients, and to analyze the Association between different trajectory groups and patient prognosis. In addition, this study will further analyze its Association with nutritional intake and nutritional indicators, thereby assessing the potential value of prealbumin change trajectories in terms of the adequacy and effectiveness of nutritional support for critically ill patients.",[564,543,29],"ICU",[566,567,568],"prealbumin","Critically Ill Patients","Prognosis","2026-02-10",{"date":571,"type":38},"2026-02-17",{"date":573,"type":22},"2026-03-15",{"date":575,"type":22},"2027-04-15",{"name":552,"class":86},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":595,"leadSponsor":597,"locationsCount":46},"100624603","phase-1-pin-in-combination-with-sintilimab-in-previously-treated-pmmrmss-crc-with-hepatic-metastases-100624603","NCT07411781","PIN in Combination With Sintilimab in Previously Treated pMMR\u002FMSS CRC With Hepatic Metastases","Treatment of Pyroptosis-inducible Newcasstle Disease Oncolytic Virus (PIN) Plus Sintilimab (Anti-PD1 Antibody) for Patients With Advanced pMMR\u002F MSS Colorectal Cancer With Hepatic Metastases:an Open-Label, Randomized,Phase I Study.","Inclusion Criteria:\n\n1. Age 18-75 (inclusive).\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and Estimated life expectancy of more than 3 months.\n3. Histologically confirmed diagnosis of unresectable locally advanced, recurrent or metastatic CRC with hepatic metastases have failed at least two lines of prior treatment.\n4. Tumor tissues were identified as pMMR by immunohistochemistry (IHC) method or MSS by polymerase chain reaction (PCR).\n5. At least one measurable lesion at baseline according to investigators Response Evaluation Criteria in Solid Tumours 1.1 (RECIST 1.1).\n6. Patients with injectable lesions (those suitable for direct injection or injection with the assistance of medical imaging) in the liver metastatic lesions, defined as follows: at least one injectable lesion in the skin, mucous membrane, subcutaneous tissue, lymph node or visceral organ with a longest diameter ≥10 mm.\n7. Subjects are willing to accept tumor rebiopsy in the process of this study.\n8. Adequate organ function as defined by the following criteria:\n\n   * Absolute neutrophil count (ANC) ≥ 1 x 10\\^9\u002FL, Platelet count ≥50 x 10\\^9\u002F L, hemoglobin (Hgb) ≥ 80g\u002FL ;\n   * Serum creatinine≤1.5 upper limit of normal (ULN) or creatinine clearance (as estimated by Cockcroft Gault) ≥60 mL\u002Fmin;\n   * Serum aspartate amino transferase (AST) and alanine aminotransferase (ALT), ≤5 x ULN ; Total serum bilirubin ≤3 x ULN);\n   * Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings;\n   * International Normalized Ratio (INR) ≤ 1.5 times the upper limit of normal (ULN), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times ULN;\n   * Baseline oxygen saturation \\>91% on room air.\n9. Previous treatments must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to \\\u003C= grade 1 toxicity (except for hematological toxicities and clinically non-significant toxicities such as alopecia).\n10. Pregnancy tests for women of childbearing age shall be negative; Both men and women agreed to use effective contraception during treatment and during the subsequent 1 year.\n11. Voluntarily participate in this clinical trial and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Participants with DNA mismatch repair-deficient or microsatellite instability-high (dMMR \u002FMSI-H) CRC.\n2. Advanced CRC without hepatic metastases.\n3. Subjects are being treated with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.\n4. Active central nervous system disease involvement (but allow patients with prior brain metastases treated at least 4 weeks prior to enrollment that are clinically stable and do not require intervention), or prior history of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 drug-related Central Nervous System (CNS) toxicity.\n5. Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management.\n6. Any serious underlying medical (eg, pulmonary, renal, hepatic,gastrointestinal, or neurological) or psychiatric condition or any issue that would limit compliance with study requirements.\n7. Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.\n8. Received cytotoxic chemicals, monoclonal antibodies, immunotherapy or other intervene within 4 weeks or 5 half-lives before enrollment.\n9. Received radiotherapy within 3 months before enrollment.\n10. Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy.\n11. The presence of uncontrollable serous membrane fluid, such as massive pleural effusion or ascites.\n12. Previous or concurrent cancer within 3 years prior to treatment start except for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\\].\n13. Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).\n14. Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation.\n15. History of allergy or intolerance to study drug components.\n16. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented.\n17. Being participating any other trials or withdraw within 4 weeks.\n18. Researchers believe that other reasons are not suitable for clinical trials.",{"count":7,"type":22},[179],"In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with anti-programmed cell death -1 (anti-PD1) antibody therapeutic regimen (sintilimab) will be evaluated in patients with advanced proficient mismatch repair\u002Fmicrosatellite stable (pMMR\u002FMSS) colorectal cancer (CRC) with hepatic metastases . A total of 25 to 30 patients are planned to be enrolled and receive PIN plus sintilimab combined treatment. It aims to:\n\n1).assess the safety and antitumor effects of the above combined treatment regimen. 2).detect the dynamic changes and molecular characteristics of PIN induced CD8+ T cells with special phenotype in peripheral blood (PB) and transformation of tumor microenvironment (TME) after the treatment with PIN. 3).evaluate the immunological or clinical predictive biomarkers for toxicity and efficacy.",[588,29],"Colorectal Cancer",[590,591],"oncolytic viruses","PD-1","2026-02-09",{"date":571,"type":38},{"date":548,"type":22},{"date":596,"type":22},"2031-03-01",{"name":598,"class":86},"Chinese PLA General Hospital",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":609,"conditions":610,"keywords":613,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":46},"100622617","evaluation-of-the-diagnostic-efficacy-of-a-v6fap-targeting-heterodimeric-probe-in-patients-with-malignant-solid-tumors-100622617","NCT07385950","Evaluation of the Diagnostic Efficacy of a αvβ6\u002FFAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors","Evaluation of Diagnostic Efficacy of a αvβ6\u002FFAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors: An Open-Label, Single-Arm, Single-Center Study","Inclusion Criteria:\n\n1. Voluntarily provide written informed consent.\n2. Age ≥ 18 years.\n3. Newly diagnosed with a clinically\u002Fradiologically suspected or pathologically confirmed malignant solid tumor, or with suspected recurrence after prior treatment.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n5. Life expectancy \\> 6 months.\n6. Participants of childbearing potential and their partners must agree to use highly effective contraception for 6 months following the last dose of the investigational agent.\n\nExclusion Criteria:\n\n1. Prior radioisotope therapy within an interval less than 10 times the physical half-life of the respective radionuclide before study administration.\n2. Concurrent participation in any other interventional clinical trial.\n3. Known allergy or hypersensitivity to the investigational agent or any of its excipients.\n4. Inability to lie still for the duration of the PET scan or any condition contraindicating PET imaging.\n5. Pregnancy or lactation.\n6. Any other condition that, in the investigator's judgment, would compromise participant safety or study integrity.","90 Years",{"count":608,"type":22},100,"Malignant tumors pose a grave threat to human health and impose a substantial burden on society. Molecular imaging, which enables non-invasive, in vivo visualization of biological processes at the molecular level, is crucial for early diagnosis and treatment monitoring, thereby improving clinical management. Currently, molecular probes targeting fibroblast activation protein (FAP) and integrin αvβ6, such as ⁶⁸Ga-labeled FAPI and ⁶⁸Ga-Trivehexin, have shown promise in oncologic PET imaging, yet each has limitations.\n\nFAP is predominantly overexpressed in cancer-associated fibroblasts within the tumor stroma, with minimal expression in normal tissues. However, radiotracers like ⁶⁸Ga-FAPI often exhibit physiological uptake in normal organs (e.g., salivary glands, pancreas, uterus), leading to elevated background signals and potentially reduced diagnostic contrast. Conversely, integrin αvβ6 is primarily expressed on tumor cell surfaces and is upregulated in many malignancies. Nonetheless, probes like ⁶⁸Ga-Trivehexin suffer from high renal retention with slow clearance and notable physiological gastrointestinal uptake, resulting in suboptimal target-to-background ratios and compromised image quality.\n\nGiven the complementary expression profiles of FAP (stroma) and integrin αvβ6 (tumor cells), we hypothesize that a bispecific molecular probe capable of simultaneously engaging both targets could achieve superior tumor targeting through a synergistic \"dual-lock\" mechanism. This prospective exploratory clinical trial aims to evaluate the diagnostic efficacy and safety of a novel bispecific probe, named ⁶⁸Ga-B6FA-01, in patients with malignant solid tumors. The ultimate goal is to develop a superior imaging strategy for early and precise tumor diagnosis, treatment response assessment, and personalized therapeutic decision-making.",[611,612,29],"PET \u002F CT","Solid Tumors",[614,615,616,617],"integrin αVβ6","FAP","PET imaging","Diagnostic efficacy","2026-01-26",{"date":478,"type":38},{"date":621,"type":22},"2026-01-15",{"date":42,"type":22},{"name":624,"class":86},"Zhongnan Hospital",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":633,"enrollmentInfo":634,"targetDuration":4,"studyType":23,"phases":636,"briefSummary":637,"conditions":638,"keywords":641,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":46},"100587036","the-effect-of-exercise-on-metabolic-alteration-100587036","NCT06923163","The Effect of Exercise on Metabolic Alteration","Metabolic Response of Sedentary Participants to a Long-term Exercise Intervention","Exercise","Inclusion Criteria:\n\n* Sedentary individuals\n* BMI ≥ 18.5 kg\u002Fm2\n\nExclusion Criteria:\n\n* Individuals who have undergone major surgery in the past 6 months (excluding tooth extraction);\n* Individuals on long-term medication;\n* Individuals with metabolic and cardiovascular diseases such as diabetes, hypoglycemia, and hypertension;\n* Individuals with exercise-related injuries, including joint diseases and fractures;\n* Individuals diagnosed with infectious diseases such as HIV, tuberculosis, malaria, etc.;\n* Individuals with mental and neurological disorders including anorexia nervosa;\n* Individuals who have attempted weight loss or gain through various methods in the past three months;\n* Individuals in preconception, pregnancy, and lactation periods;\n* Individuals with autism and those with metal implants in their bodies.","40 Years",{"count":635,"type":22},80,[60],"The goal of this clinical trial is to study the effectiveness of aerobic exercise in treating obesity in adults and to assess the efficacy of exercise. The primary research questions it seeks to address are as follows:\n\n* To what extent does exercise increase the total energy expenditure of participants?\n* Why and how does the energy expenditure from exercise not fully compensate for the total energy expenditure (TEE)?\n* Researchers will assess the efficacy and potential challenges of using exercise as a treatment for obesity by comparing the measurement data before exercise intervention (week 0), immediately after exercise intervention (week 12), and 8 weeks post-completion of exercise intervention (week 20).\n\nParticipants will engage in the following activities:\n\n* Engage in running sessions supervised five times a week for a duration of 12 weeks.\n* Attend laboratory sessions both before and after the exercise intervention period for metabolic and anthropometric measurements, as well as sample collection.\n* Return to the laboratory for further metabolic and anthropometric measurements and sample collection8 weeks post-completion of exercise intervention.",[639,640,29],"Sedentary Behavior","Healthy Participants",[642,643,644],"Metabolic response","Energy expenditure","Energy compensation","2026-01-19",{"date":647,"type":38},"2026-01-21",{"date":649,"type":38},"2025-05-01",{"date":651,"type":22},"2027-12",{"name":653,"class":86},"Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":17,"minAge":662,"maxAge":663,"enrollmentInfo":664,"targetDuration":4,"studyType":23,"phases":666,"briefSummary":667,"conditions":668,"keywords":673,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":690},"100606257","optimizing-the-aya-survivors-coping-and-emotional-needs-toolkit-100606257","NCT07173205","Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit","R00 Full Factorial Trial: Optimizing ASCENT","ASCENT","Inclusion Criteria:\n\n* Age at enrollment (adolescents 15-17, emerging adults 18-25, young adults 26-39)\n* Age at diagnosis (adolescents 12-17, emerging adults 15-25, young adults 15-39)\n* Time since completion of treatment: 1 month to 5 years\n* Language: Fluent in English (spoken and written)\n* Technology: Own smart phone with data plan\n\nExclusion Criteria:\n\n* Mental Health: Current diagnosis of severe or persistent mental illness\n* Suicidality: Severe suicidal ideation (including plan and intent)","15 Years","39 Years",{"count":665,"type":22},208,[60],"Our team has developed a digital intervention that aims to help adolescent and young adult cancer survivors (AYAs) manage symptoms of depression. This tool includes one psychoeducation component and four components that are based on evidence-based interventions for depression. The goal of this study is to test which component or combination of components meaningfully contribute to improvements in depressive symptoms among AYAs.",[669,670,671,672,29],"Depression","Cancer","Adolescent","Young Adult",[674,675,676,677,678,679,680],"AYA","Adolescent and Young Adult","Cancer Survivorship","Depressive Symptoms","Digital Mental Health","Multiphase Optimization Strategy","Full Factorial Trial","2026-01-05",{"date":683,"type":38},"2026-01-07",{"date":685,"type":38},"2025-10-25",{"date":687,"type":22},"2027-03",{"name":689,"class":86},"East Carolina University",2,{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":326,"enrollmentInfo":698,"targetDuration":4,"studyType":23,"phases":699,"briefSummary":700,"conditions":701,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":705,"lastUpdatePostDateStruct":706,"startDateStruct":708,"completionDateStruct":710,"leadSponsor":712,"locationsCount":46},"100610697","interaction-between-white-potato-consumption-and-meal-timing-on-glycemic-response-and-appetite-in-adults-100610697","NCT07230951","Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appetite in Adults","Interaction Between White Potato Consumption and Meal Timing on Glycemic Response, Subjective Appetite, and Energy Intake in Adults.","Inclusion Criteria:\n\n* 18 - 65 years\n* within the healthy body weight range \\[body mass index (BMI) between 18.5 - 24.9 kg\u002Fm2\\].\n\nExclusion Criteria:\n\n* have a previous diagnosis of diabetes and gastrointestinal, liver or kidney disease;\n* have had a major medical or surgical event within the past 6 months;\n* have had any significant weight fluctuation in the past 6-months;\n* are taking medication that may influence dependent measures;\n* are or have been on a diet within the past 6 months;\n* skip breakfast or are unable to consume test treatment food.",{"count":21,"type":22},[60],"The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.",[102,29,702,703,704],"Appetite","Glycemic Response","Mealtiming","2025-11-13",{"date":707,"type":38},"2025-11-17",{"date":709,"type":38},"2025-10-30",{"date":711,"type":22},"2027-10",{"name":713,"class":86},"Toronto Metropolitan University"]